Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study

Exelixis (NASDAQ: EXEL) already markets cabozantinib as a treatment for kidney cancer and liver cancer; its latest results suggest it may secure approval for its use in prostate cancer someday, too.